Dianthus Therapeutics Accelerates CIDP Trial After Early GO Decision
Event summary
- Dianthus Therapeutics achieved an early GO decision in its Phase 3 CAPTIVATE trial for claseprubart in CIDP, with 20 confirmed responders achieved before the planned 40 participants.
- The company reported $514.4 million in cash as of December 31, 2025, providing runway into 2028.
- Phase 3 trial for claseprubart in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026, with top-line results anticipated in 2H’28.
- Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing, with top-line results on track for 2H’26.
- Phase 1 healthy volunteer data for DNTH212 anticipated in 2H’26, with an update on indication prioritization planned for 1H’26.
The big picture
Dianthus Therapeutics is positioning itself as a leader in developing next-generation therapies for severe autoimmune diseases. The early GO decision in the CAPTIVATE trial for claseprubart in CIDP underscores the company's ability to accelerate clinical development, while its robust cash position provides a strong foundation for continued innovation. The strategic focus on neuromuscular disorders with high unmet medical needs aligns with broader industry trends toward targeted therapies and personalized medicine.
What we're watching
- Trial Momentum
- Whether the early GO decision in the CAPTIVATE trial will translate into sustained positive results in Part B and beyond.
- Financial Runway
- How Dianthus Therapeutics will allocate its $514.4 million cash position to support multiple clinical trials through 2028.
- Pipeline Progress
- The pace at which claseprubart and DNTH212 advance through their respective clinical stages and the potential for regulatory approvals.
Related topics